| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 218.8 | 178.9 | 192.8 |
| Other income | 0.5 | 2.6 | 1.7 |
| Total income | 219.3 | 181.5 | 194.5 |
| Profit before exceptional items & tax | 33.5 | 30.0 | 26.5 |
| Profit before tax | 33.5 | 30.0 | 26.5 |
| Net profit | 25.6 | 23.0 | 20.1 |
| Operating margin | 15.3% | 16.5% | 13.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +27.40% |
|---|---|
| Net profit, quarter on quarter | +11.30% |
| Revenue, year on year | +13.50% |
| Operating profit, year on year | +33.10% |
| Operating profit, quarter on quarter | +20.40% |
BSE results filing, NSE: VENUSREM. Figures extracted from the filing.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,330.20
- Market cap
- ₹1,778 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 14.6×Sector 46.1×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Venus Remedies Other Announcement
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Venus Remedies Management Change
Venus Remedies Ltd announced the appointment and re-appointment of several Directors, including Executive and Independent Directors, following approval at its 37th Annual General Meeting.